Symbol="KALV"
AssetType="Common Stock"
Name="Kalvista Pharmaceuticals Inc"
Description="KalVista Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, discovers, develops, and markets small-molecule protease inhibitors for illnesses with unmet needs. The company is headquartered in Cambridge, Massachusetts."
CIK="1348911"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="3181 PORTER DRIVE, PALO ALTO, CA, US"
FiscalYearEnd="April"
LatestQuarter="2023-04-30"
MarketCapitalization="331101000"
EBITDA="-94511000"
PERatio="None"
PEGRatio="0"
BookValue="4.712"
DividendPerShare="0"
DividendYield="0"
EPS="-4.14"
RevenuePerShareTTM="0.214"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.307"
ReturnOnEquityTTM="-0.537"
RevenueTTM="3824000"
GrossProfitTTM="-70167000"
DilutedEPSTTM="-4.14"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0.307"
AnalystTargetPrice="20.67"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="107.42"
PriceToBookRatio="0.979"
EVToRevenue="76.33"
EVToEBITDA="-0.246"
Beta="1.031"
num_52WeekHigh="17.06"
num_52WeekLow="4.12"
num_50DayMovingAverage="9.68"
num_200DayMovingAverage="7.64"
SharesOutstanding="34169400"
DividendDate="2016-11-22"
ExDividendDate="None"
symbol="KALV"
open="10.09"
high="10.49"
low="9.53"
price="9.63"
volume="176734.00"
latest_trading_day="2023-07-12"
previous_close="9.80"
change="-0.17"
change_percent="-1.7347%"
aroon_positive_momentum_days="83"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Strong Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="83"
Volume_recent_avg="242150"
Change_recent_avg="0.02"
Delta_recent_avg="0.46"
Variance_recent_avg="0.23"
Change_ratio_recent_avg="0.13"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="83"
Aroon_momentum_negative="17"
image_negative_thumbnail_id_1="120"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0056.jpeg"
image_negative_thumbnail_id_2="1108"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0141.jpeg"
image_neutral_thumbnail_id_1="528"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0071.jpeg"
image_neutral_thumbnail_id_2="572"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0027.jpeg"
image_positive_thumbnail_id_1="641"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0067.jpeg"
image_positive_thumbnail_id_2="624"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0084.jpeg"
image_professor_thumbnail_id_1="1173"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0007.jpeg"
image_professor_thumbnail_id_2="1172"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0006.jpeg"
